Register for real-time alerts, custom portfolio, and market movers
Period:
Draw Mode:
| Volume | 21,708 |
|
|||||
| News | - | ||||||
| Day High | 3.30 | Low High |
|||||
| Day Low | 3.22 | ||||||
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| MEI Pharma Inc | MEIP | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded
|
|
|---|---|---|---|---|
| 0.0017 | 0.05% | 3.2517 | 12:40:30 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 3.30 | 3.22 | 3.30 | 3.25 |
| Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
|---|---|---|---|---|---|
| 73 | 21,708 | $ 3.25 | $ 70,636 | - | 3.20 - 7.97 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 12:43:02 | 1 | $ 3.34 | USD |
MEI Pharma Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 21.65M | 6.66M | - | 48.82M | -31.84M | -4.78 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
MEI Pharma News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical MEIP Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 3.63 | 3.79 | 3.20 | 3.25 | 14,626 | -0.3783 | -10.42% |
| 1 Month | 3.55 | 4.1473 | 3.20 | 3.75 | 20,179 | -0.2983 | -8.40% |
| 3 Months | 4.60 | 4.97 | 3.20 | 4.05 | 22,126 | -1.35 | -29.31% |
| 6 Months | 6.74 | 7.8734 | 3.20 | 5.79 | 36,514 | -3.49 | -51.76% |
| 1 Year | 4.99 | 7.97 | 3.20 | 6.35 | 44,984 | -1.74 | -34.84% |
| 3 Years | 67.00 | 78.20 | 3.20 | 19.70 | 1,267,738 | -63.75 | -95.15% |
| 5 Years | 57.80 | 91.50 | 3.20 | 31.96 | 1,119,763 | -54.55 | -94.37% |
MEI Pharma Description
| MEI Pharma Inc is focused on the clinical development of novel therapies for cancer. The company's clinical drug candidate includes Pracinostat, an orally available histone deacetylase inhibitor for the treatment of patients with acute myeloid leukemia and myelodysplastic syndrome. Its clinical development portfolio also includes Zandelisib, an oral inhibitor of phosphatidylinositide 3-kinase delta for the treatment of patients with recurrent chronic lymphocytic leukemia or follicular non-Hodgkin's lymphoma; and ME-344, an isoflavone-based mitochondrial inhibitor for the treatment of HER2-negative breast cancer and Pracinostat, an oral histone deacetylase inhibitor. Geographically, all the business activities function through the region of the United States. |
